Sachi Bio

Sachi Bio is a Genetic Tools and Therapeutics company that aims to revolutionize the field of genetic manipulation with their proprietary platform. The company, founded in 2019, focuses on developing nucleic acid molecules designed to target any gene in any organism. Their platform integrates various scientific disciplines, including systems biology, synthetic biology, chemistry, nanotechnology, and cell culture to create high-precision tools and therapeutics capable of probing and disrupting genes in a diverse range of organisms in a facile and multiplexed manner.

Sachi Bio's novel approach involves the use of design and build modules to generate hundreds to thousands of hybrid molecules, referred to as nano oligomers, in a matter of days. These proprietary nano oligomers exhibit enhanced specificity, transport, and reduced off-targeting, marking a significant advancement in the field of genetic manipulation. The company's platform enables the creation of precise, multiplexed, cloning-free genetic tools that can effectively manipulate gene regulation by switching genes on and off.

The company operates within the Analytics, Biotechnology, Health and Wellness industries. Despite the absence of specific headquarters and recent investment data, Sachi Bio's pioneering technology and innovative approach position them as a promising player in the biotechnology sector, with the potential to influence significant advancements in genetic research and therapeutics.